Document Classification

Section Type: RESULTS

Text: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7. 85 % in the group that received 90 mg of ticagrelor twice daily, 7. 77 % in the group that received 60 mg of ticagrelor twice daily, and 9. 04 % in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0. 85 ; 95 % confidence interval [CI], 0. 75 to 0. 96 ; P = 0. 008 ; hazard ratio for 60 mg of ticagrelor vs. placebo, 0. 84 ; 95 % CI, 0. 74 to 0. 95 ; P = 0. 004).